Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Januvia is a prescription dipeptidyl peptidase-4 inhibitor containing sitagliptin. It is used with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Current tablets contain 25 mg, 50 mg, or 100 mg.
read more about januvia ...Sitagliptin inhibits DPP-4, which slows the breakdown of active incretin hormones. Higher incretin concentrations increase glucose-dependent insulin release and decrease glucagon secretion when blood glucose is elevated.
Januvia is used in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. It is not used for type 1 diabetes. Current labeling states that Januvia has not been studied in patients with a history of pancreatitis.
The recommended dose is 100 mg once daily with or without food. Patients with an estimated glomerular filtration rate from 30 to less than 45 mL per minute per 1.73 square meters receive 50 mg once daily. Patients with an estimated glomerular filtration rate below 30, including those with end-stage renal disease requiring dialysis, receive 25 mg once daily.
Serious concerns include acute pancreatitis, heart failure risk associated with the DPP-4 inhibitor class, acute kidney failure, severe hypersensitivity reactions, severe joint pain, and bullous pemphigoid. Low blood glucose can occur more frequently when Januvia is combined with insulin or an insulin secretagogue.
Januvia improves glycemic control in adults with type 2 diabetes mellitus when used with diet and exercise.
The standard dose is 100 mg once daily with or without food.
Yes. The dose is reduced to 50 mg or 25 mg once daily at the kidney function thresholds specified in current labeling.
No. Current labeling states that Januvia should not be used in patients with type 1 diabetes.
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/26052984/. Date Accessed October 6, 2026.
Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/17130196/. Date Accessed October 6, 2026.
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone. https://pubmed.ncbi.nlm.nih.gov/17130197/. Date Accessed October 6, 2026.
JANUVIA (Sitagliptin) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f85a48d0-0407-4c50-b0fa-7673a160bf01. Date Accessed October 6, 2026.
Sitagliptin: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a606023.html. Date Accessed October 6, 2026.